• Biodesix and Capital Royalty Close Financing Transaction

    February 12, 2014 Biodesix Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced that the company closed a structured debt financing with Capital Royalty Partners L.P.  The transaction provides Biodesix®with up to $20 million of capital. “Capital Royalty’s financing structure has been uniquely tailored to suit our capital needs, especially during this growth phase of ... Read more
  • Biodesix Adds to Series E Financing

    January 13, 2014 Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced that the company increased the size of its recent offering of series E preferred shares in a follow-on sale. In addition to the $8.3 million of series E shares sold a month ago, the company brought in another $6.1 million, for ... Read more
  • Biodesix Closes Series E Financing

    December 3, 2013 Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced that the company closed an $8.3 million Series E preferred equity financing. New funds accounted for $4.3 million of the round and the remaining $4 million came from the conversion of a convertible note. Existing Biodesix shareholders provided all of the ... Read more
  • Biodesix to Present at World CDx

    November 15, 2013 Session Examines Use of Proteomics and Mass Spec to Improve Biomarker Validation BOSTON AND BOULDER, Colo.– November 13, 2013 – Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced that Vice President of Business Development and Strategic Marketing, Paul Beresford, Ph.D., will present at the 2013 World CDx Summit taking place in Boston, November 12-15, 2013. ... Read more
  • Biodesix® Announces Additional Data in Phase III Lung Cancer Diagnostic Study

    October 28, 2013 Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced additional data from the Phase III clinical trial for its serum protein test, VeriStrat®. Results were presented at the 15thWorld Conference on Lung Cancer in Sydney, Australia. “PROSE data confirms VeriStrat can predict differential treatment outcomes in second-line advanced NCLSC patients; VeriStrat is ... Read more
  • Biodesix Secures Medicare Coverage for VeriStrat Test

    June 20, 2013 Coverage of Predictive Biomarker Test Enables Lung Cancer Patients to Benefit From More-Informed Treatment Decisions Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced that Novitas Solutions, the Medicare Administrative Contractor for the region that includes Colorado, has established coverage for the company’s VeriStrat test. VeriStrat, a clinically validated blood-based protein test, helps physicians ... Read more
  • Biodesix Announces Results in Phase III Lung Cancer Diagnostic Study; First Prospective Biomarker-Stratified Validation Study in Oncology

    June 3, 2013 Results of independent trial confirm VeriStrat’s ability to predict differential treatment outcomes between erlotinib and chemotherapy Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced results of the recently completed phase III clinical trial for its VeriStrat® test. Data confirms that the non-invasive, blood-based protein diagnostic is predictive of differential treatment outcomes ... Read more
  • Biodesix to Announce Results of VeriStrat® Biomarker Study

    May 21, 2013 Independent Phase III Data to Be Presented at the 2013 ASCO Annual Meeting Biodesix, Inc., announced that final results of the first completed biomarker-stratified, validation study in oncology will be presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31st – June 4th, 2013. The Randomized Proteomic Stratified Phase III Study of Second Line ... Read more
  • Biodesix Closes Series D Financing

    April 12, 2013 Biodesix, Inc., a molecular diagnostics company advancing the development of innovative products for personalizing medicine, announced today that the company closed on $8.8 million in a follow-on sale of its Series D preferred shares.  All funds were provided by existing shareholders of the company.  The investment will be used for ongoing development of the company’s ... Read more
  • Peer-Reviewed Study Confirms VeriStrat® Test from Biodesix Provides Useful Information for Physicians in Managing Patients with Lung Cancer

    April 2, 2013 Physicians Adopting Novel Serum Test to Help Recommend Course of Treatment for Patients with Advanced Disease Biodesix, Inc., a molecular diagnostic company dedicated to personalizing medicine, today announced the online release of a peer-reviewed study demonstrating that physicians are using the company’s VeriStrat test to help guide treatment decisions for patients with advanced non-small lung cell cancer (NSCLC). ... Read more